Transcription factor regulatory networks in mammary epithelial development and tumorigenesis

Oncogene

Volumn 29, Issue 19, 2010, Pages 2753-2759

  Siegel, P M ^a   Muller, W J ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Breast cancer; Elf; GATA 3; Mammary gland development; STAT; Transcription factor networks

Indexed keywords

STAT5A PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELF 5; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG;

BREAST EPITHELIUM; BREAST METASTASIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FATE; CELL MATURATION; HUMAN; INVOLUTION; LUNG ALVEOLUS CELL; MAMMARY GLAND; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TUMOR GROWTH;

ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINEAGE; HUMANS; MAMMARY GLANDS, ANIMAL; STEM CELLS; TRANSCRIPTION FACTORS;

EID: 77952419251     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.43     Document Type: Review

References (57)

1. Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC et al. (2007). Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 9: 201-209.
2. Asselin-Labat ML, Vaillant F, Shackleton M, Bouras T, Lindeman GJ, Visvader JE. (2008). Delineating the epithelial hierarchy in the mouse mammary gland. Cold Spring Harb Symp Quant Biol 73: 469-478.
3. Brisken C. (2002). Hormonal control of alveolar development and its implications for breast carcinogenesis. J Mammary Gland Biol Neoplasia 7: 39-48.
4. Campbell LL, Polyak K. (2007). Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 6: 2332-2338. (Pubitemid 350058682)
5. Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K et al. (1999). Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 13: 2604-2616.
6. Choi YS, Chakrabarti R, Escamilla-Hernandez R, Sinha S. (2009). Elf5 conditional knockout mice reveal its role as a master regulator in mammary alveolar development: failure of Stat5 activation and functional differentiation in the absence of Elf5. Dev Biol 329: 227-241.
7. Clevenger CV. (2003). Role of prolactin/prolactin receptor signaling in human breast cancer. Breast Dis 18: 75-86.
8. Cotarla I, Ren S, Zhang Y, Gehan E, Singh B, Furth PA. (2004). Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 108: 665-671.
9. Dydensborg AB, Rose AA, Wilson BJ, Grote D, Paquet M, Giguere V et al. (2009). GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene 28: 2634-2642.
10. Eirew P, Stingl J, Raouf A, Turashvili G, Aparicio S, Emerman JT et al. (2008). A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med 14: 1384-1389.
11. Fang SH, Chen Y, Weigel RJ. (2009). GATA-3 as a marker of hormone response in breast cancer. J Surg Res 157: 290-295.
12. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555-567.
13. Grimm SL, Rosen JM. (2003). The role of C/EBPbeta in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 8: 191-204.
14. Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G et al. (2006). Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 126: 489-502.
15. Guy CT, Cardiff RD, Muller WJ. (1992). Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12: 954-961.
16. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS et al. (2009). Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69: 4116-4124.
17. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z et al. (2007). Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8: R76.
18. Humphreys RC, Bierie B, Zhao L, Raz R, Levy D, Hennighausen L. (2002). Deletion of Stat3 blocks mammary gland involution and extends functional competence of the secretory epithelium in the absence of lactogenic stimuli. Endocrinology 143: 3641-3650.
19. Jackson-Fisher AJ, Bellinger G, Shum E, Duong JK, Perkins AS, Gassmann M et al. (2006). Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. Oncogene 25: 5664-5672.
20. Jones FE, Welte T, Fu XY, Stern DF. (1999). ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J Cell Biol 147: 77-88.
21. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ et al. (2008a). GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13: 141-152.
22. Kouros-Mehr H, Kim JW, Bechis SK, Werb Z. (2008b). GATA-3 and the regulation of the mammary luminal cell fate. Curr Opin Cell Biol 20: 164-170.
23. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. (2006). GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127: 1041-1055.
24. Lamarca HL, Visbal AP, Creighton CJ, Liu H, Zhang Y, Behbod F et al. (2010). C/EBPbeta Regulates stem cell activity and specifies luminal cell fate in the mammary gland. Stem Cells (e-pub ahead of print).
25. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH et al. (2009). Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15: 907-913.
26. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ et al. (2003). Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163: 2113-2126.
27. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. (1997). Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 11: 179-186.
28. McDaniel SM, Rumer KK, Biroc SL, Metz RP, Singh M, Porter W et al. (2006). Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am J Pathol 168: 608-620.
29. Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D et al. (2005). Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res 65: 11259-11264.
30. Miyoshi K, Shillingford JM, Smith GH, Grimm SL, Wagner KU, Oka T et al. (2001). Signal transducer and activator of transcription (Stat) 5 controls the proliferation and differentiation of mammary alveolar epithelium. J Cell Biol 155: 531-542.
31. Molyneux G, Regan J, Smalley MJ. (2007). Mammary stem cells and breast cancer. Cell Mol Life Sci 64: 3248-3260.
32. Naylor MJ, Ormandy CJ. (2007). Gata-3 and mammary cell fate. Breast Cancer Res 9: 302.
33. Oakes SR, Naylor MJ, Asselin-Labat ML, Blazek KD, Gardiner-Garden M, Hilton HN et al. (2008). The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev 22: 581-586.
34. Pensa S, Watson CJ, Poli V. (2009). Stat3 and the inflammation/acute phase response in involution and breast cancer. J Mammary Gland Biol Neoplasia 14: 121-129.
35. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. (2000). Molecular portraits of human breast tumours. Nature 406: 747-752.
36. Polyak K. (2007a). Breast cancer stem cells: a case of mistaken identity? Stem Cell Rev 3: 107-109. (Pubitemid 350129711)
37. Polyak K. (2007b). Breast cancer: origins and evolution. J Clin Invest 117: 3155-3163.
38. Prat A, Perou CM. (2009). Mammary development meets cancer genomics. Nat Med 15: 842-844.
39. Ranger JJ, Levy DE, Shahalizadeh S, Hallett M, Muller WJ. (2009). Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. Cancer Res 69: 6823-6830.
40. Ren S, Cai HR, Li M, Furth PA. (2002). Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 21: 4335-4339.
41. Schedin P, OBrien J, Rudolph M, Stein T, Borges V. (2007). Microenvironment of the involuting mammary gland mediates mammary cancer progression. J Mammary Gland Biol Neoplasia 12: 71-82.
42. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML et al. (2006). Generation of a functional mammary gland from a single stem cell. Nature 439: 84-88.
43. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874.
44. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423.
45. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A et al. (2003). Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393-10398.
46. Sternlicht MD, Kouros-Mehr H, Lu P, Werb Z. (2006). Hormonal and local control of mammary branching morphogenesis. Differentiation 74: 365-381.
47. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D et al. (2006a). Purification and unique properties of mammary epithelial stem cells. Nature 439: 993-997.
48. Stingl J, Raouf A, Eirew P, Eaves CJ. (2006b). Deciphering the mammary epithelial cell hierarchy. Cell Cycle 5: 1519-1522.
49. Thangaraju M, Rudelius M, Bierie B, Raffeld M, Sharan S, Hennighausen L et al. (2005). C/EBPdelta is a crucial regulator of pro-apoptotic gene expression during mammary gland involution. Development 132: 4675-4685.
50. Tiffen PG, Omidvar N, Marquez-Almuina N, Croston D, Watson CJ, Clarkson RW. (2008). A dual role for oncostatin M signaling in the differentiation and death of mammary epithelial cells in vivo. Mol Endocrinol 22: 2677-2688.
51. Tvorogov D, Sundvall M, Kurppa K, Hollmen M, Repo S, Johnson MS et al. (2009). Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. J Biol Chem 284: 5582-5591.
52. Visvader JE. (2009). Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev 23: 2563-2577.
53. Vomachka AJ, Pratt SL, Lockefeer JA, Horseman ND. (2000). Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth. Oncogene 19: 1077-1084.
54. Wang S, Yuan Y, Liao L, Kuang SQ, Tien JC, OMalley BW et al. (2009). Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. Proc Natl Acad Sci USA 106: 151-156.
55. Yamaji D, Na R, Feuermann Y, Pechhold S, Chen W, Robinson GW et al. (2009). Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A. Genes Dev 23: 2382-2387.
56. Zhang Y, Sif S, DeWille J. (2007). The mouse C/EBPdelta gene promoter is regulated by STAT3 and Sp1 transcriptional activators, chromatin remodeling and c-Myc repression. J Cell Biochem 102: 1256-1270.
57. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J et al. (2007). Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 104: 16158-16163.